The limitation of current study is that the mouse model used has different aspects from the human acute angle closure glaucoma such as the site of putative pressure-induced damage in glaucoma, the anatomy of the optic nerve of the mouse and the higher level but shorter duration of induced IOP.4 A number of CXCR3 antagonists are in clinical development for treating diseases such as arthritis and psoriasis,36 future evaluation of the effects of these antagonists on patients with acute glaucoma would validate the role of CXCR3 in human subjects and may lead to novel therapies. This evidence concerns the gene CXCR3 and glaucoma.